Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where DaRue A. Prieto is active.

Publication


Featured researches published by DaRue A. Prieto.


Molecular & Cellular Proteomics | 2003

Characterization of the Low Molecular Weight Human Serum Proteome

Radhakrishna S. Tirumalai; King C. Chan; DaRue A. Prieto; Haleem J. Issaq; Thomas P. Conrads; Timothy D. Veenstra

Serum potentially carries an archive of important histological information whose determination could serve to improve early disease detection. The analysis of serum, however, is analytically challenging due to the high dynamic concentration range of constituent protein/peptide species, necessitating extensive fractionation prior to mass spectrometric analyses. The low molecular weight (LMW) serum proteome is that protein/peptide fraction from which high molecular weight proteins, such as albumin, immunoglobulins, transferrin, and lipoproteins, have been removed. This LMW fraction is made up of several classes of physiologically important proteins such as cytokines, chemokines, peptide hormones, as well as proteolytic fragments of larger proteins. Centrifugal ultrafiltration of serum was used to remove the large constituent proteins resulting in the enrichment of the LMW proteins/peptides. Because albumin is known to bind and transport small molecules and peptides within the circulatory system, the centrifugal ultrafiltration was conducted under solvent conditions effecting the disruption of protein-protein interactions. The LMW serum proteome sample was digested with trypsin, fractionated by strong cation exchange chromatography, and analyzed by microcapillary reversed-phase liquid chromatography coupled on-line with electrospray ionization tandem mass spectrometry. Analysis of the tandem mass spectra resulted in the identification of over 340 human serum proteins; however, not a single peptide from serum albumin was observed. The large number of proteins identified demonstrates the efficacy of this method for the removal of large abundant proteins and the enrichment of the LMW serum proteome.


Analytical Chemistry | 2003

SELDI-TOF MS for diagnostic proteomics.

Haleem J. Issaq; Thomas P. Conrads; DaRue A. Prieto; Radhakrishna S. Tirumalai; Timothy D. Veenstra

By combining chromatographic retention with MS, SELDI-TOF MS can generate protein profiles from as little as 1 μL of serum or as few as 25–50 cells.


Science | 2008

Del-1, an Endogenous Leukocyte-Endothelial Adhesion Inhibitor, Limits Inflammatory Cell Recruitment

Eun Young Choi; Emmanouil Chavakis; Marcus Czabanka; Harald Langer; Line Fraemohs; Matina Economopoulou; Ramendra K. Kundu; Alessia Orlandi; Ying Yi Zheng; DaRue A. Prieto; Christie M. Ballantyne; Stephanie L. Constant; William C. Aird; Thalia Papayannopoulou; Carl G. Gahmberg; Mark C. Udey; Peter Vajkoczy; Thomas Quertermous; Stefanie Dimmeler; Christian Weber; Triantafyllos Chavakis

Leukocyte recruitment to sites of infection or inflammation requires multiple adhesive events. Although numerous players promoting leukocyte-endothelial interactions have been characterized, functionally important endogenous inhibitors of leukocyte adhesion have not been identified. Here we describe the endothelially derived secreted molecule Del-1 (developmental endothelial locus–1) as an anti-adhesive factor that interferes with the integrin LFA-1–dependent leukocyte-endothelial adhesion. Endothelial Del-1 deficiency increased LFA-1–dependent leukocyte adhesion in vitro and in vivo. Del-1–/– mice displayed significantly higher neutrophil accumulation in lipopolysaccharide-induced lung inflammation in vivo, which was reversed in Del-1/LFA-1 double-deficient mice. Thus, Del-1 is an endogenous inhibitor of inflammatory cell recruitment and could provide a basis for targeting leukocyte-endothelial interactions in disease.


Journal of Clinical Investigation | 2014

MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis

Atsushi Terunuma; Nagireddy Putluri; Prachi Mishra; Ewy Mathe; Tiffany H. Dorsey; Ming Yi; Tiffany A. Wallace; Haleem J. Issaq; Ming Zhou; J. Keith Killian; Holly Stevenson; Edward D. Karoly; King C. Chan; Susmita Samanta; DaRue A. Prieto; Tiffany Hsu; Sarah J. Kurley; Vasanta Putluri; Rajni Sonavane; Daniel C. Edelman; Jacob Wulff; Adrienne M. Starks; Yinmeng Yang; Rick A. Kittles; Harry G. Yfantis; Dong H. Lee; Olga B. Ioffe; Rachel Schiff; Robert M. Stephens; Paul S. Meltzer

Metabolic profiling of cancer cells has recently been established as a promising tool for the development of therapies and identification of cancer biomarkers. Here we characterized the metabolomic profile of human breast tumors and uncovered intrinsic metabolite signatures in these tumors using an untargeted discovery approach and validation of key metabolites. The oncometabolite 2-hydroxyglutarate (2HG) accumulated at high levels in a subset of tumors and human breast cancer cell lines. We discovered an association between increased 2HG levels and MYC pathway activation in breast cancer, and further corroborated this relationship using MYC overexpression and knockdown in human mammary epithelial and breast cancer cells. Further analyses revealed globally increased DNA methylation in 2HG-high tumors and identified a tumor subtype with high tissue 2HG and a distinct DNA methylation pattern that was associated with poor prognosis and occurred with higher frequency in African-American patients. Tumors of this subtype had a stem cell-like transcriptional signature and tended to overexpress glutaminase, suggestive of a functional relationship between glutamine and 2HG metabolism in breast cancer. Accordingly, 13C-labeled glutamine was incorporated into 2HG in cells with aberrant 2HG accumulation, whereas pharmacologic and siRNA-mediated glutaminase inhibition reduced 2HG levels. Our findings implicate 2HG as a candidate breast cancer oncometabolite associated with MYC activation and poor prognosis.


BioTechniques | 2005

Liquid Tissue™: proteomic profiling of formalin-fixed tissues

DaRue A. Prieto; Brian L. Hood; Marlene Darfler; Thomas G. Guiel; David A. Lucas; Thomas P. Conrads; Timothy D. Veenstra; David B. Krizman

Identification and quantitation of candidate biomarker proteins in large numbers of individual tissues is required to validate specific proteins, or panels of proteins, for clinical use as diagnostic, prognostic, toxicological, or therapeutic markers. Mass spectrometry (MS) provides an exciting analytical methodology for this purpose. Liquid Tissue MS protein preparation allows researchers to utilize the vast, already existing, collections offormalin-fixed paraffin-embedded (FFPE) tissues for the procurement of peptides and the analysis across a variety of MS platforms.


Journal of Biological Chemistry | 2009

Engineered Human Antibody Constant Domains with Increased Stability

Rui Gong; Bang K. Vu; Yang Feng; DaRue A. Prieto; Marzena A. Dyba; Joseph D. Walsh; Ponraj Prabakaran; Timothy D. Veenstra; Sergey G. Tarasov; Rieko Ishima; Dimiter S. Dimitrov

The immunoglobulin (Ig) constant CH2 domain is critical for antibody effector functions. Isolated CH2 domains are promising as scaffolds for construction of libraries containing diverse binders that could also confer some effector functions. However, previous work has shown that an isolated murine CH2 domain is relatively unstable to thermally induced unfolding. To explore unfolding mechanisms of isolated human CH2 and increase its stability γ1 CH2 was cloned and a panel of cysteine mutants was constructed. Human γ1 CH2 unfolded at a higher temperature (Tm = 54.1 °C, as measured by circular dichroism) than that previously reported for a mouse CH2 (41 °C). One mutant (m01) was remarkably stable (Tm = 73.8 °C). Similar results were obtained by differential scanning calorimetry. This mutant was also significantly more stable than the wild-type CH2 against urea induced unfolding (50% unfolding at urea concentration of 6.8 m versus 4.2 m). The m01 was highly soluble and monomeric. The existence of the second disulfide bond in m01 and its correct position were demonstrated by mass spectrometry and nuclear magnetic resonance spectroscopy, respectively. The loops were on average more flexible than the framework in both CH2 and m01, and the overall secondary structure was not affected by the additional disulfide bond. These data suggest that a human CH2 domain is relatively stable to unfolding at physiological temperature, and that both CH2 and the highly stable mutant m01 are promising new scaffolds for the development of therapeutics against human diseases.


Drug Discovery Today | 2004

Proteomic patterns for early cancer detection

Timothy D. Veenstra; DaRue A. Prieto; Thomas P. Conrads

The advent of proteomics has brought with it the hope of discovering novel biomarkers that can be used to diagnose diseases, predict susceptibility, and monitor progression. Much of this effort has focused on the mass spectral identification of the thousands of proteins that populate complex biosystems such as serum and tissues. A revolutionary approach in proteomic pattern analysis has emerged as an effective method for the early diagnosis of diseases such as ovarian, breast, and prostate cancer. This technology is capable of analyzing hundreds of clinical samples per day and has the potential to be a novel, highly sensitive diagnostic tool for the early detection of diseases, or as a predictor of response to therapy.


The FASEB Journal | 1999

Cycling of human dendritic cell effector phenotypes in response to TNF-alpha: modification of the current 'maturation' paradigm and implications for in vivo immunoregulation.

Edward L. Nelson; Susan L. Strobl; Jeff Subleski; DaRue A. Prieto; William Kopp; Peter J. Nelson

Dendritic cells (DCs) are potent antigen presenting cells reported to undergo irreversible functional ‘maturation’ in response to inflammatory signals such as TNF‐α. The current paradigm holds that this DC maturation event is required for full functional capacity and represents terminal differentiation of this cell type, culminating in apoptotic cell death. This provides a possible mechanism for avoiding dysregulated immunostimulatory activity, but imposes constraints on the capacity of DCs to influence subsequent immune responses and to participate in immunological memory. We report that the cell surface and functional effects induced by TNF‐α are reversible and reinducible. These effects are accompanied by a concordant modulation of cytokine mRNA expression that includes the induction of proinflammatory factors (IL‐15, IL‐12, LT‐α, LT‐β, TNF‐α, RANTES) which is coincident with the down‐regulation of counter‐regulatory cytokines (IL‐10, TGF‐βl, TGF‐β2, IL‐1 RA, MCP‐1). The resultant net effect is a dendritic cell activation state characterized by a transient proinflammatory posture. These results demonstrate that 1) human DCs do not undergo terminal ‘maturation’ in response to TNF‐α, 2) DC phenotypes are more pleiotropic than previously thought, and 3) DCs are potential immunoregulatory effector cells with implications for control of immune responses in both in vivo and in vitro systems.—Nelson, E. L., Strobl, S., Subleski, J., Prieto, D., Kopp, W. C., Nelson, P. J. Cycling of human dendritic cell effector phenotypes in response to TNF‐α: modification of the current ‘maturation’ paradigm and implications for in vivo immunoregulation. Cycling of human dendritic cell effector phenotypes in response to TNF‐α: modification of the current ‘maturation’ paradigm and implications for in vivo immunoregulation. FASEB J. 13, 2021–2030 (1999)


Disease Markers | 2004

The use of urine proteomic and metabonomic patterns for the diagnosis of interstitial cystitis and bacterial cystitis

Que N. Van; John R. Klose; David A. Lucas; DaRue A. Prieto; Brian T. Luke; Jack R. Collins; Stanley K. Burt; Gwendolyn N. Chmurny; Haleem J. Issaq; Thomas P. Conrads; Timothy D. Veenstra; Susan Keay

The advent of systems biology approaches that have stemmed from the sequencing of the human genome has led to the search for new methods to diagnose diseases. While much effort has been focused on the identification of disease-specific biomarkers, recent efforts are underway toward the use of proteomic and metabonomic patterns to indicate disease. We have developed and contrasted the use of both proteomic and metabonomic patterns in urine for the detection of interstitial cystitis (IC). The methodology relies on advanced bioinformatics to scrutinize information contained within mass spectrometry (MS) and high-resolution proton nuclear magnetic resonance (1H-NMR) spectral patterns to distinguish IC-affected from non-affected individuals as well as those suffering from bacterial cystitis (BC). We have applied a novel pattern recognition tool that employs an unsupervised system (self-organizing-type cluster mapping) as a fitness test for a supervised system (a genetic algorithm). With this approach, a training set comprised of mass spectra and 1H-NMR spectra from urine derived from either unaffected individuals or patients with IC is employed so that the most fit combination of relative, normalized intensity features defined at precise m/z or chemical shift values plotted in n-space can reliably distinguish the cohorts used in training. Using this bioinformatic approach, we were able to discriminate spectral patterns associated with IC-affected, BC-affected, and unaffected patients with a success rate of approximately 84%.


Breast Cancer Research and Treatment | 2003

Venezuelan Equine Encephalitis Replicon Immunization Overcomes Intrinsic Tolerance and Elicits Effective Anti-tumor Immunity to the ‘Self’ tumor-associated antigen, neu in a Rat Mammary Tumor Model

Edward L. Nelson; DaRue A. Prieto; Terri G. Alexander; Peter Pushko; Loreen A. Lofts; Jonathan O. Rayner; Kurt I. Kamrud; Bolyn Fralish; Jonathan F. Smith

Many tumor-associated antigens (TAAs) represent ‘self’ antigens and as such, are subject to the constraints of immunologic tolerance. There are significant barriers to eliciting anti-tumor immune responses of sufficient magnitude. We have taken advantage of a Venezuelan equine encephalitis-derived alphavirus replicon vector system with documented in vivo tropism for immune system dendritic cells. We have overcome the intrinsic tolerance to the ‘self’ TAA rat neu and elicited an effective anti-tumor immune response using this alphavirus replicon vector system and a designed target antigen in a rigorous rat mammary tumor model. We have demonstrated the capacity to generate 50% protection in tumor challenge experiments (p = 0.004) and we have confirmed the establishment of immunologic memory by both second tumor challenge and Winn Assay (p = 0.009). Minor antibody responses were identified and supported the establishment of T helper type 1 (Th1) anti-tumor immune responses by isotype. Animals surviving in excess of 300 days with established effective anti-tumor immunity showed no signs of autoimmune phenomena. Together these experiments support the establishment of T lymphocyte dependent, Th1-biased anti-tumor immune responses to a non-mutated ‘self’ TAA in an aggressive tumor model. Importantly, this tumor model is subject to the constraints of immunologic tolerance present in animals with normal developmental, temporal, and anatomical expression of a non-mutated TAA. These data support the continued development and potential clinical application of this alphaviral replicon vector system and the use of appropriately designed target antigen sequences for anti-tumor immunotherapy.

Collaboration


Dive into the DaRue A. Prieto's collaboration.

Top Co-Authors

Avatar

Timothy D. Veenstra

Science Applications International Corporation

View shared research outputs
Top Co-Authors

Avatar

Haleem J. Issaq

Science Applications International Corporation

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Josip Blonder

Science Applications International Corporation

View shared research outputs
Top Co-Authors

Avatar

King C. Chan

Science Applications International Corporation

View shared research outputs
Top Co-Authors

Avatar

Donald J. Johann

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Xiaoying Ye

Science Applications International Corporation

View shared research outputs
Top Co-Authors

Avatar

David A. Lucas

Science Applications International Corporation

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge